IMU has been very disappointing and is the worst pick out of my 4 selections. Down 65% so far this year, nearly 12% down this month. It's knocked my average around a lot.
I can't see Dec making much difference to the return now. As I said before, very disappointing.
Another recurring disappointment for my portfolio that tests my patience on the thesis that good biotech research takes time and money to reap outsized returns. IMU has secured another $46M in convertible notes and expects another $11M in FY 2023 R&D rebates. Will this be enough to bring one of their clinical trial candidates to commercialisation or outcomes good enough to attract M&A attention? That's the gamble for me.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.